Acura Pharmaceuticals, Inc.
ACUR
$0.02
$0.0191,900.00%
| Weiss Ratings | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Unrated | |||
| Risk Index | Unrated | |||
| Risk Grade | U | |||
| Reward Grade | U | |||
| Rating Factors | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | Unrated | |||
| Growth Index | Unrated | |||
| Efficiency Index | Unrated | |||
| Solvency Index | Unrated | |||
| Total Return Index | Unrated | |||
| Volatility Index | Unrated | |||
| Beta / Standard Deviation | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -628.20 | |||
| Price History | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 1,011.11% | |||
| 30-Day Total Return | 1,566.67% | |||
| 60-Day Total Return | 769.57% | |||
| 90-Day Total Return | 1,328.57% | |||
| Year to Date Total Return | 9,900.00% | |||
| 1-Year Total Return | 376.19% | |||
| 2-Year Total Return | -60.00% | |||
| 3-Year Total Return | -95.29% | |||
| 5-Year Total Return | -94.12% | |||
| 52-Week High % Change | -97.34% | |||
| 52-Week Low % Change | 9,900.00% | |||
| Price | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.75 | |||
| 52-Week Low Price | $0.00 | |||
| 52-Week Low Price (Date) | Dec 31, 2024 | |||
| 52-Week High Price (Date) | Dec 17, 2024 | |||
| Valuation | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.33M | |||
| Enterprise Value | -- | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.03 | |||
| Earnings Per Share Growth | 25.94% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 0.67 | |||
| Price/Book (Q) | 9.52 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $0.02 | |||
| Enterprise Value/EBITDA (TTM) | -- | |||
| Enterprise Value/EBIT | -- | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 75.56M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 847 705 7709 | |||
| Address | 616 N. North Court Palatine, IL 60067 | |||
| Website | www.acurapharm.com | |||
| Country | United States | |||
| Year Founded | 1935 | |||
| Profitability | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -49.35% | |||
| Profit Margin | -51.26% | |||
| Management Effectiveness | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -38.42% | |||
| Return on Equity | -- | |||
| Income Statement | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 2.25M | |||
| Total Revenue (TTM) | 2.25M | |||
| Revenue Per Share | $0.03 | |||
| Gross Profit (TTM) | 635.00K | |||
| EBITDA (TTM) | -1.03M | |||
| EBIT (TTM) | -1.11M | |||
| Net Income (TTM) | -1.15M | |||
| Net Income Avl. to Common (TTM) | -1.15M | |||
| Total Revenue Growth (Q YOY) | -34.15% | |||
| Earnings Growth (Q YOY) | 61.36% | |||
| EPS Diluted (TTM) | -0.03 | |||
| EPS Diluted Growth (Q YOY) | 83.33% | |||
| Balance Sheet | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 89.00K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 845.00K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 135.00K | |||
| Current Ratio (Q) | 0.862 | |||
| Book Value Per Share (Q) | $0.00 | |||
| Total Assets (Q) | 1.41M | |||
| Total Current Liabilities (Q) | 980.00K | |||
| Total Debt (Q) | 324.00K | |||
| Total Liabilities (Q) | 1.27M | |||
| Total Common Equity (Q) | 135.00K | |||
| Cash Flow | ACUR - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | -8.00K | |||
| Net Change in Cash (TTM) | -404.00K | |||
| Levered Free Cash Flow (TTM) | -410.60K | |||
| Cash from Operations (TTM) | -396.00K | |||
